EQUITY (Details) |
9 Months Ended |
|---|---|
|
Oct. 31, 2024
$ / shares
shares
| |
| EQUITY | |
| January 31, 2024 | shares | 32,972,900 |
| Vested | shares | 32,972,900 |
| Weighted average grant date fair value per share beginning | $ 0.005 |
| Vested | 0.005 |
| Weighted average grant date fair value per share ending | $ 0 |
| Weighted average remaining contractual life, begin (Years) | 8 months 12 days |
| Weighted average remaining contractual life, end (Years) | 0 years |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of non-vested options outstanding. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Weighted average grant-date fair value of non-vested options outstanding. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Weighted average grant-date fair value of options vested. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|